APO Research
Talk to an analyst

APO RESEARCH · REPORT

Lipid Metabolism Disease Drug

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Lipid Metabolism Disease Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

22 December 2025191 pages

Choose your research edition.

Industry ResearchLipid Metabolism Disease Drug Industry Research Report 2026123 pages · $2,950 USDIndustry Growth & TrendsGlobal Lipid Metabolism Disease Drug Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Lipid Metabolism Disease Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Lipid Metabolism Disease Drug Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Lipid Metabolism Disease Drug Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global Lipid Metabolism Disease Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Lipid Metabolism Disease Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Lipid Metabolism Disease Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Lipid Metabolism Disease Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Lipid Metabolism Disease Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Lipid Metabolism Disease Drug include Takeda Pharmaceutical, Novartis, Merck, Astra Zeneca, Metsubishi Tanabe Pharma, LG Life Science, Kythera, KOWA and Fuji yakuhin, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Lipid Metabolism Disease Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Lipid Metabolism Disease Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Lipid Metabolism Disease Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Lipid Metabolism Disease Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Lipid Metabolism Disease Drug Segment by Company

Takeda Pharmaceutical

Novartis

Merck

Astra Zeneca

Metsubishi Tanabe Pharma

LG Life Science

Kythera

KOWA

Fuji yakuhin

Boehringer Ingelheim

Lipid Metabolism Disease Drug Segment by Type

OTC

Rx Drugs

Lipid Metabolism Disease Drug Segment by Application

Hospital

Retail Pharmacy

Lipid Metabolism Disease Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Lipid Metabolism Disease Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Lipid Metabolism Disease Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Lipid Metabolism Disease Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Lipid Metabolism Disease Drug market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Lipid Metabolism Disease Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Lipid Metabolism Disease Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Lipid Metabolism Disease Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Lipid Metabolism Disease Drug Industry Trends Table 2. Lipid Metabolism Disease Drug Industry Drivers Table 3. Lipid Metabolism Disease Drug Industry Opportunities and Challenges Table 4. Lipid Metabolism Disease Drug Industry Restraints Table 5. Global Lipid Metabolism Disease Drug Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Lipid Metabolism Disease Drug Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Lipid Metabolism Disease Drug Sales by Manufacturers (k units) & (2021-2026) Table 8. Global Lipid Metabolism Disease Drug Sales Market Share by Manufacturers Table 9. Global Lipid Metabolism Disease Drug Average Sales Price (US$/unit) of Manufacturers (2021-2026) Table 10. Global Lipid Metabolism Disease Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Lipid Metabolism Disease Drug Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Lipid Metabolism Disease Drug Manufacturers, Product Type & Application Table 13. Global Lipid Metabolism Disease Drug Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Lipid Metabolism Disease Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of OTC Table 17. Major Manufacturers of Rx Drugs Table 18. Global Lipid Metabolism Disease Drug Sales by Type 2021 VS 2025 VS 2032 (k units) Table 19. Global Lipid Metabolism Disease Drug Sales by Type (2021-2026) & (k units) Table 20. Global Lipid Metabolism Disease Drug Sales by Type (2027-2032) & (k units) Table 21. Global Lipid Metabolism Disease Drug Sales Market Share by Type (2021-2026) Table 22. Global Lipid Metabolism Disease Drug Sales Market Share by Type (2027-2032) Table 23. Global Lipid Metabolism Disease Drug Revenue by Type 2021 VS 2025 VS 2032 (k units) Table 24. Global Lipid Metabolism Disease Drug Revenue by Type (2021-2026) & (k units) Table 25. Global Lipid Metabolism Disease Drug Revenue by Type (2027-2032) & (k units) Table 26. Global Lipid Metabolism Disease Drug Revenue Market Share by Type (2021-2026) Table 27. Global Lipid Metabolism Disease Drug Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Hospital Table 29. Major Manufacturers of Retail Pharmacy Table 30. Global Lipid Metabolism Disease Drug Sales by Application 2021 VS 2025 VS 2032 (k units) Table 31. Global Lipid Metabolism Disease Drug Sales by Application (2021-2026) & (k units) Table 32. Global Lipid Metabolism Disease Drug Sales by Application (2027-2032) & (k units) Table 33. Global Lipid Metabolism Disease Drug Sales Market Share by Application (2021-2026) Table 34. Global Lipid Metabolism Disease Drug Sales Market Share by Application (2027-2032) Table 35. Global Lipid Metabolism Disease Drug Revenue by Application 2021 VS 2025 VS 2032 (k units) Table 36. Global Lipid Metabolism Disease Drug Revenue by Application (2021-2026) & (k units) Table 37. Global Lipid Metabolism Disease Drug Revenue by Application (2027-2032) & (k units) Table 38. Global Lipid Metabolism Disease Drug Revenue Market Share by Application (2021-2026) Table 39. Global Lipid Metabolism Disease Drug Revenue Market Share by Application (2027-2032) Table 40. Global Lipid Metabolism Disease Drug Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 41. Global Lipid Metabolism Disease Drug Sales by Region (2021-2026) & (k units) Table 42. Global Lipid Metabolism Disease Drug Sales Market Share by Region (2021-2026) Table 43. Global Lipid Metabolism Disease Drug Sales Forecasted by Region (2027-2032) & (k units) Table 44. Global Lipid Metabolism Disease Drug Sales Forecasted Market Share by Region (2027-2032) Table 45. North America Lipid Metabolism Disease Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 46. North America Lipid Metabolism Disease Drug Sales by Country (2021-2026) & (k units) Table 47. North America Lipid Metabolism Disease Drug Sales by Country (2027-2032) & (k units) Table 48. Europe Lipid Metabolism Disease Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 49. Europe Lipid Metabolism Disease Drug Sales by Country (2021-2026) & (k units) Table 50. Europe Lipid Metabolism Disease Drug Sales by Country (2027-2032) & (k units) Table 51. Asia Pacific Lipid Metabolism Disease Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 52. Asia Pacific Lipid Metabolism Disease Drug Sales by Country (2021-2026) & (k units) Table 53. Asia Pacific Lipid Metabolism Disease Drug Sales by Country (2027-2032) & (k units) Table 54. South America, Middle East and Africa Lipid Metabolism Disease Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 55. South America, Middle East and Africa Lipid Metabolism Disease Drug Sales by Country (2021-2026) & (k units) Table 56. South America, Middle East and Africa Lipid Metabolism Disease Drug Sales by Country (2027-2032) & (k units) Table 57. Global Lipid Metabolism Disease Drug Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Lipid Metabolism Disease Drug Revenue by Region (2021-2026) & (US$ Million) Table 59. Global Lipid Metabolism Disease Drug Revenue by Region (2027-2032) & (US$ Million) Table 60. Global Lipid Metabolism Disease Drug Revenue Market Share by Region (2021-2026) Table 61. Global Lipid Metabolism Disease Drug Revenue Market Share by Region (2027-2032) Table 62. Takeda Pharmaceutical Company Information Table 63. Takeda Pharmaceutical Business Overview Table 64. Takeda Pharmaceutical Lipid Metabolism Disease Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 65. Takeda Pharmaceutical Lipid Metabolism Disease Drug Product Portfolio Table 66. Takeda Pharmaceutical Recent Development Table 67. Novartis Company Information Table 68. Novartis Business Overview Table 69. Novartis Lipid Metabolism Disease Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Novartis Lipid Metabolism Disease Drug Product Portfolio Table 71. Novartis Recent Development Table 72. Merck Company Information Table 73. Merck Business Overview Table 74. Merck Lipid Metabolism Disease Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Merck Lipid Metabolism Disease Drug Product Portfolio Table 76. Merck Recent Development Table 77. Astra Zeneca Company Information Table 78. Astra Zeneca Business Overview Table 79. Astra Zeneca Lipid Metabolism Disease Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. Astra Zeneca Lipid Metabolism Disease Drug Product Portfolio Table 81. Astra Zeneca Recent Development Table 82. Metsubishi Tanabe Pharma Company Information Table 83. Metsubishi Tanabe Pharma Business Overview Table 84. Metsubishi Tanabe Pharma Lipid Metabolism Disease Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. Metsubishi Tanabe Pharma Lipid Metabolism Disease Drug Product Portfolio Table 86. Metsubishi Tanabe Pharma Recent Development Table 87. LG Life Science Company Information Table 88. LG Life Science Business Overview Table 89. LG Life Science Lipid Metabolism Disease Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. LG Life Science Lipid Metabolism Disease Drug Product Portfolio Table 91. LG Life Science Recent Development Table 92. Kythera Company Information Table 93. Kythera Business Overview Table 94. Kythera Lipid Metabolism Disease Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 95. Kythera Lipid Metabolism Disease Drug Product Portfolio Table 96. Kythera Recent Development Table 97. KOWA Company Information Table 98. KOWA Business Overview Table 99. KOWA Lipid Metabolism Disease Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 100. KOWA Lipid Metabolism Disease Drug Product Portfolio Table 101. KOWA Recent Development Table 102. Fuji yakuhin Company Information Table 103. Fuji yakuhin Business Overview Table 104. Fuji yakuhin Lipid Metabolism Disease Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 105. Fuji yakuhin Lipid Metabolism Disease Drug Product Portfolio Table 106. Fuji yakuhin Recent Development Table 107. Boehringer Ingelheim Company Information Table 108. Boehringer Ingelheim Business Overview Table 109. Boehringer Ingelheim Lipid Metabolism Disease Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 110. Boehringer Ingelheim Lipid Metabolism Disease Drug Product Portfolio Table 111. Boehringer Ingelheim Recent Development Table 112. Key Raw Materials Table 113. Raw Materials Key Suppliers Table 114. Lipid Metabolism Disease Drug Distributors List Table 115. Lipid Metabolism Disease Drug Customers List Table 116. Research Programs/Design for This Report Table 117. Authors List of This Report Table 118. Secondary Sources Table 119. Primary Sources List of Figures Figure 1. Lipid Metabolism Disease Drug Product Image Figure 2. Global Lipid Metabolism Disease Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Lipid Metabolism Disease Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Lipid Metabolism Disease Drug Sales (2021-2032) & (k units) Figure 5. Global Lipid Metabolism Disease Drug Average Price (US$/unit) & (2021-2032) Figure 6. Global Top 5 and 10 Lipid Metabolism Disease Drug Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. OTC Image Figure 9. Rx Drugs Image Figure 10. Global Lipid Metabolism Disease Drug Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 11. Global Lipid Metabolism Disease Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global Lipid Metabolism Disease Drug Sales Market Share by Type (2021-2032) Figure 13. Global Lipid Metabolism Disease Drug Revenue by Type (2021 VS 2025 VS 2032) & (k units) Figure 14. Global Lipid Metabolism Disease Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global Lipid Metabolism Disease Drug Revenue Market Share by Type (2021-2032) Figure 16. Hospital Image Figure 17. Retail Pharmacy Image Figure 18. Global Lipid Metabolism Disease Drug Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 19. Global Lipid Metabolism Disease Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 20. Global Lipid Metabolism Disease Drug Sales Market Share by Application (2021-2032) Figure 21. Global Lipid Metabolism Disease Drug Revenue by Application (2021 VS 2025 VS 2032) & (k units) Figure 22. Global Lipid Metabolism Disease Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 23. Global Lipid Metabolism Disease Drug Revenue Market Share by Application (2021-2032) Figure 24. North America Lipid Metabolism Disease Drug Sales and Growth Rate (2021-2032) & (k units) Figure 25. North America Lipid Metabolism Disease Drug Sales Market Share by Country (2021-2032) Figure 26. U.S. Lipid Metabolism Disease Drug Sales and Growth Rate (2021-2032) & (k units) Figure 27. Canada Lipid Metabolism Disease Drug Sales and Growth Rate (2021-2032) & (k units) Figure 28. Mexico Lipid Metabolism Disease Drug Sales and Growth Rate (2021-2032) & (k units) Figure 29. Europe Lipid Metabolism Disease Drug Sales and Growth Rate (2021-2032) & (k units) Figure 30. Europe Lipid Metabolism Disease Drug Sales Market Share by Country (2021-2032) Figure 31. Germany Lipid Metabolism Disease Drug Sales and Growth Rate (2021-2032) & (k units) Figure 32. France Lipid Metabolism Disease Drug Sales and Growth Rate (2021-2032) & (k units) Figure 33. U.K. Lipid Metabolism Disease Drug Sales and Growth Rate (2021-2032) & (k units) Figure 34. Italy Lipid Metabolism Disease Drug Sales and Growth Rate (2021-2032) & (k units) Figure 35. Netherlands Lipid Metabolism Disease Drug Sales and Growth Rate (2021-2032) & (k units) Figure 36. Asia Pacific Lipid Metabolism Disease Drug Sales and Growth Rate (2021-2032) & (k units) Figure 37. Asia Pacific Lipid Metabolism Disease Drug Sales Market Share by Country (2021-2032) Figure 38. China Lipid Metabolism Disease Drug Sales and Growth Rate (2021-2032) & (k units) Figure 39. Japan Lipid Metabolism Disease Drug Sales and Growth Rate (2021-2032) & (k units) Figure 40. South Korea Lipid Metabolism Disease Drug Sales and Growth Rate (2021-2032) & (k units) Figure 41. Southeast Asia Lipid Metabolism Disease Drug Sales and Growth Rate (2021-2032) & (k units) Figure 42. India Lipid Metabolism Disease Drug Sales and Growth Rate (2021-2032) & (k units) Figure 43. Australia Lipid Metabolism Disease Drug Sales and Growth Rate (2021-2032) & (k units) Figure 44. South America, Middle East and Africa Lipid Metabolism Disease Drug Sales and Growth Rate (2021-2032) & (k units) Figure 45. South America, Middle East and Africa Lipid Metabolism Disease Drug Sales Market Share by Country (2021-2032) Figure 46. Brazil Lipid Metabolism Disease Drug Sales and Growth Rate (2021-2032) & (k units) Figure 47. South Africa Lipid Metabolism Disease Drug Sales and Growth Rate (2021-2032) & (k units) Figure 48. Saudi Arabia Lipid Metabolism Disease Drug Sales and Growth Rate (2021-2032) & (k units) Figure 49. Turkey Lipid Metabolism Disease Drug Sales and Growth Rate (2021-2032) & (k units) Figure 50. Argentina Lipid Metabolism Disease Drug Sales and Growth Rate (2021-2032) & (k units) Figure 51. UAE Lipid Metabolism Disease Drug Sales and Growth Rate (2021-2032) & (k units) Figure 52. Egypt Lipid Metabolism Disease Drug Sales and Growth Rate (2021-2032) & (k units) Figure 53. Chile Lipid Metabolism Disease Drug Sales and Growth Rate (2021-2032) & (k units) Figure 54. Global Lipid Metabolism Disease Drug Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 55. Global Lipid Metabolism Disease Drug Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 56. North America Lipid Metabolism Disease Drug Revenue (2021-2032) & (US$ Million) Figure 57. North America Lipid Metabolism Disease Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 58. Europe Lipid Metabolism Disease Drug Revenue (2021-2032) & (US$ Million) Figure 59. Europe Lipid Metabolism Disease Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 60. Asia-Pacific Lipid Metabolism Disease Drug Revenue (2021-2032) & (US$ Million) Figure 61. Asia-Pacific Lipid Metabolism Disease Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. South America, Middle East and Africa Lipid Metabolism Disease Drug Revenue (2021-2032) & (US$ Million) Figure 63. South America, Middle East and Africa Lipid Metabolism Disease Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Lipid Metabolism Disease Drug Value Chain Figure 65. Manufacturing Cost Structure Figure 66. Lipid Metabolism Disease Drug Production Mode & Process Figure 67. Direct Comparison with Distribution Share Figure 68. Distributors Profiles Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • OTC
  • Rx Drugs
Applications
  • Hospital
  • Retail Pharmacy
Companies covered
  • Takeda Pharmaceutical
  • Novartis
  • Merck
  • Astra Zeneca
  • Metsubishi Tanabe Pharma
  • LG Life Science
  • Kythera
  • KOWA
  • Fuji yakuhin
  • Boehringer Ingelheim

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Lipid Metabolism Disease Drug Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Lipid Metabolism Disease Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Lipid Metabolism Disease Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Lipid Metabolism Disease Drug Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Lipid Metabolism Disease Drug Market Dynamics
  1. 2.1 Lipid Metabolism Disease Drug Industry Trends
  2. 2.2 Lipid Metabolism Disease Drug Industry Drivers
  3. 2.3 Lipid Metabolism Disease Drug Industry Opportunities and Challenges
  4. 2.4 Lipid Metabolism Disease Drug Industry Restraints
3 Lipid Metabolism Disease Drug Market by Manufacturers
  1. 3.1 Global Lipid Metabolism Disease Drug Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Lipid Metabolism Disease Drug Sales by Manufacturers (2021-2026)
  3. 3.3 Global Lipid Metabolism Disease Drug Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Lipid Metabolism Disease Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Lipid Metabolism Disease Drug Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Lipid Metabolism Disease Drug Manufacturers, Product Type & Application
  7. 3.7 Global Lipid Metabolism Disease Drug Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Lipid Metabolism Disease Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Lipid Metabolism Disease Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Lipid Metabolism Disease Drug Tier 1, Tier 2, and Tier 3
4 Lipid Metabolism Disease Drug Market by Type
  1. 4.1 Lipid Metabolism Disease Drug Type Introduction
  2. 4.1.1 OTC
  3. 4.1.2 Rx Drugs
  4. 4.2 Global Lipid Metabolism Disease Drug Sales by Type
  5. 4.2.1 Global Lipid Metabolism Disease Drug Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Lipid Metabolism Disease Drug Sales by Type (2021-2032)
  7. 4.2.3 Global Lipid Metabolism Disease Drug Sales Market Share by Type (2021-2032)
  8. 4.3 Global Lipid Metabolism Disease Drug Revenue by Type
  9. 4.3.1 Global Lipid Metabolism Disease Drug Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Lipid Metabolism Disease Drug Revenue by Type (2021-2032)
  11. 4.3.3 Global Lipid Metabolism Disease Drug Revenue Market Share by Type (2021-2032)
5 Lipid Metabolism Disease Drug Market by Application
  1. 5.1 Lipid Metabolism Disease Drug Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Retail Pharmacy
  4. 5.2 Global Lipid Metabolism Disease Drug Sales by Application
  5. 5.2.1 Global Lipid Metabolism Disease Drug Sales by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Lipid Metabolism Disease Drug Sales by Application (2021-2032)
  7. 5.2.3 Global Lipid Metabolism Disease Drug Sales Market Share by Application (2021-2032)
  8. 5.3 Global Lipid Metabolism Disease Drug Revenue by Application
  9. 5.3.1 Global Lipid Metabolism Disease Drug Revenue by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Lipid Metabolism Disease Drug Revenue by Application (2021-2032)
  11. 5.3.3 Global Lipid Metabolism Disease Drug Revenue Market Share by Application (2021-2032)
6 Global Lipid Metabolism Disease Drug Sales by Region
  1. 6.1 Global Lipid Metabolism Disease Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Lipid Metabolism Disease Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Lipid Metabolism Disease Drug Sales by Region (2021-2026)
  4. 6.2.2 Global Lipid Metabolism Disease Drug Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Lipid Metabolism Disease Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Lipid Metabolism Disease Drug Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Lipid Metabolism Disease Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Lipid Metabolism Disease Drug Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Lipid Metabolism Disease Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Lipid Metabolism Disease Drug Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Lipid Metabolism Disease Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Lipid Metabolism Disease Drug Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Lipid Metabolism Disease Drug Revenue by Region
  1. 7.1 Global Lipid Metabolism Disease Drug Revenue by Region
  2. 7.1.1 Global Lipid Metabolism Disease Drug Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Lipid Metabolism Disease Drug Revenue by Region (2021-2026)
  4. 7.1.3 Global Lipid Metabolism Disease Drug Revenue by Region (2027-2032)
  5. 7.1.4 Global Lipid Metabolism Disease Drug Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Lipid Metabolism Disease Drug Revenue (2021-2032)
  8. 7.2.2 North America Lipid Metabolism Disease Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Lipid Metabolism Disease Drug Revenue (2021-2032)
  11. 7.3.2 Europe Lipid Metabolism Disease Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Lipid Metabolism Disease Drug Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Lipid Metabolism Disease Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Lipid Metabolism Disease Drug Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Lipid Metabolism Disease Drug Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Takeda Pharmaceutical
  2. 8.1.1 Takeda Pharmaceutical Company Information
  3. 8.1.2 Takeda Pharmaceutical Business Overview
  4. 8.1.3 Takeda Pharmaceutical Lipid Metabolism Disease Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Takeda Pharmaceutical Lipid Metabolism Disease Drug Product Portfolio
  6. 8.1.5 Takeda Pharmaceutical Recent Developments
  7. 8.2 Novartis
  8. 8.2.1 Novartis Company Information
  9. 8.2.2 Novartis Business Overview
  10. 8.2.3 Novartis Lipid Metabolism Disease Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Novartis Lipid Metabolism Disease Drug Product Portfolio
  12. 8.2.5 Novartis Recent Developments
  13. 8.3 Merck
  14. 8.3.1 Merck Company Information
  15. 8.3.2 Merck Business Overview
  16. 8.3.3 Merck Lipid Metabolism Disease Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Merck Lipid Metabolism Disease Drug Product Portfolio
  18. 8.3.5 Merck Recent Developments
  19. 8.4 Astra Zeneca
  20. 8.4.1 Astra Zeneca Company Information
  21. 8.4.2 Astra Zeneca Business Overview
  22. 8.4.3 Astra Zeneca Lipid Metabolism Disease Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Astra Zeneca Lipid Metabolism Disease Drug Product Portfolio
  24. 8.4.5 Astra Zeneca Recent Developments
  25. 8.5 Metsubishi Tanabe Pharma
  26. 8.5.1 Metsubishi Tanabe Pharma Company Information
  27. 8.5.2 Metsubishi Tanabe Pharma Business Overview
  28. 8.5.3 Metsubishi Tanabe Pharma Lipid Metabolism Disease Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Metsubishi Tanabe Pharma Lipid Metabolism Disease Drug Product Portfolio
  30. 8.5.5 Metsubishi Tanabe Pharma Recent Developments
  31. 8.6 LG Life Science
  32. 8.6.1 LG Life Science Company Information
  33. 8.6.2 LG Life Science Business Overview
  34. 8.6.3 LG Life Science Lipid Metabolism Disease Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 LG Life Science Lipid Metabolism Disease Drug Product Portfolio
  36. 8.6.5 LG Life Science Recent Developments
  37. 8.7 Kythera
  38. 8.7.1 Kythera Company Information
  39. 8.7.2 Kythera Business Overview
  40. 8.7.3 Kythera Lipid Metabolism Disease Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Kythera Lipid Metabolism Disease Drug Product Portfolio
  42. 8.7.5 Kythera Recent Developments
  43. 8.8 KOWA
  44. 8.8.1 KOWA Company Information
  45. 8.8.2 KOWA Business Overview
  46. 8.8.3 KOWA Lipid Metabolism Disease Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 KOWA Lipid Metabolism Disease Drug Product Portfolio
  48. 8.8.5 KOWA Recent Developments
  49. 8.9 Fuji yakuhin
  50. 8.9.1 Fuji yakuhin Company Information
  51. 8.9.2 Fuji yakuhin Business Overview
  52. 8.9.3 Fuji yakuhin Lipid Metabolism Disease Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Fuji yakuhin Lipid Metabolism Disease Drug Product Portfolio
  54. 8.9.5 Fuji yakuhin Recent Developments
  55. 8.10 Boehringer Ingelheim
  56. 8.10.1 Boehringer Ingelheim Company Information
  57. 8.10.2 Boehringer Ingelheim Business Overview
  58. 8.10.3 Boehringer Ingelheim Lipid Metabolism Disease Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Boehringer Ingelheim Lipid Metabolism Disease Drug Product Portfolio
  60. 8.10.5 Boehringer Ingelheim Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Lipid Metabolism Disease Drug Value Chain Analysis
  2. 9.1.1 Lipid Metabolism Disease Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Lipid Metabolism Disease Drug Production Mode & Process
  6. 9.2 Lipid Metabolism Disease Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Lipid Metabolism Disease Drug Distributors
  9. 9.2.3 Lipid Metabolism Disease Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst